drugset / Trial / NCT00319956

Trial II of Lung Protection With Azithromycin in the Preterm Infant

NCT00319956

Phase 2 Completed 220 enrolled Hubert Ballard American Lung Association · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.

Timeline

Start
2004-09
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 5 mg/kg Intravenous